期刊
ANTIVIRAL THERAPY
卷 17, 期 6, 页码 1119-1131出版社
SAGE PUBLICATIONS LTD
DOI: 10.3851/IMP2424
关键词
-
资金
- Achillion
- Anadys
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Gilead
- GlobeImmune
- Novartis
- Pfizer
- Pharmasset
- Roche/Genentech
- Schering/Merck
- Tibotec/Janssen
- Vertex
- Zymogenetics
Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treatment-experienced patients and shortens the duration of treatment for over half of treatment-naive patients. This review describes the clinical data supporting the approval and use of telaprevir and boceprevir, the algorithm for the use of these drugs, their adverse effects, as well as their important drug-drug interactions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据